Skip to main content
Harm Reduction Journal logoLink to Harm Reduction Journal
. 2021 Feb 19;18:23. doi: 10.1186/s12954-021-00465-9

Correction to: Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France

Salim Mezaache 1,2,, Patrizia Carrieri 1,2, Laelia Briand‑Madrid 1,2, Virginie Laporte 3, Alain Morel 4, Daniela Rojas Castro 1,2,5, Perrine Roux 1,2
PMCID: PMC7893719  PMID: 33607993

Correction to: Mezaache et al. Harm Reduct J (2021) 18:11 https://doi.org/10.1186/s12954-021-00460-0

Following publication of the original article [1], the authors identified an error in Table 1.

Table 1.

Factors associated with general willingness to receive intravenous buprenorphine treatment in the study sample

N (%) or
Median [IQR]
Univariate analysis n = 209 Multivariate analysis n = 197
OR [95CI%] p AOR [95CI%] p
Questionnaire
 Online 162 (78) 0
 Face-to-face 47 (22) 0.97 [0.53; 1.77] 0.924
Gender
 Male 164 (79) 0
 Female 43 (21) 0.75 [0.41; 1.35] 0.335
Age
 For 1 year 34 [28–41] 0.99 [0.96; 1.02] 0.619
Stable housing
 No 81 (39) 0
 Yes 127 (61) 0.72 [0.43; 1.22] 0.228
Employment
 No 147 (70) 0
 Yes 62 (30) 0.76 [0.44; 1.30] 0.319
Duration of opioid use
 For 1 year 8 [4–11] 1.01 [0.96; 1.06] 0.614
Duration of buprenorphine use
 For 1 year 6 [4–10] 1.02 [0.97; 1.07.] 0.528
Daily buprenorphine dose
 For 1 mg 11 [8–16] 1.04 [1.00; 1.09] 0.052 1.05 [1.00; 1.10] 0.043
Daily injection frequency
 For 1 injection 3 [2–4] 1.12 [0.98; 1.27] 0.086
Buprenorphine non-prescribed
 No 187 (93) 0
 Yes 13 (7) 3.98 [1.09; 14.47] 0.036 4.82 [1.30; 17.85] 0.019
Main reason for injecting buprenorphine
 To get “high” 27 (15) 0
 To avoid withdrawal symptoms or to feel good enough for daily functioning 103 (59) 0.96 [0.44; 2.10] 0.929
 For the pleasure of the act 41 (23) 2.23 [1.08; 4.61] 0.030
Other non-opioid drugs used
 No 49 (24) 0
 Yes 156 (76) 1.03 [0.56; 1.89] 0.934
Alcohol consumption
 No 124 (59) 0
 Yes 85 (41) 0.99 [0.60; 1.67] 0.997
Lifetime number of injection-related complications (0–10)
 ≤ 5 complications 175 (84) 0
 > 5 complications 34 (16) 2.29 [1.08; 4.88] 0.031 2.28 [1.05; 4.93] 0.037
Lifetime history of overdose
 No 168 (80) 0
 Yes 41 (20) 1.26 [0.65; 2.47] 0.493
Self-reported HCV status
 No 129 (66) 0
 Yes 66 (34) 0.87 [0.50; 1.53] 0.647

The correct table is given below.

The original article has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Mezaache et al. Harm Reduct J (2021) 18:11. https://doi.org/10.1186/s12954-021-00460-0

Articles from Harm Reduction Journal are provided here courtesy of BMC

RESOURCES